Citi analyst Yigal Nochomovitz closed his 90-day catalyst watch on Aldeyra after the company reported Phase 3 data for reproxalap in allergic conjunctivitis. On February 15, Nochomovitz predicted the stock could be up 75% to 125% on positive data. The analyst today boosted his price target for Aldeyra to $28 from $23 and keeps a Buy rating on the name. The stock in afternoon trading is up 36%, or $2.56, to $9.70.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.